Becton, Dickinson and Co. | BDX - Fremdkapital

Aktienkurs
144.48
Täglich Wechseln
0.30 0.21%
Monatlich
-7.10%
Jährlich
-16.13%
Q2 Prognose
146.34




Fremdkapital Veränderung Datum
Abbott USD 29.64B 19.74B 2026-03
Agilent USD 3.05B 0 2025-12
Align Technology USD 0 0 2024-12
AngioDynamics USD 5.6M 100K 2025-09
Avanos Medical USD 87.3M 3M 2026-03
Baxter International USD 8.62B 852M 2026-03
Becton, Dickinson and Co. USD 14.71B 2.21B 2026-03
Bio-Rad Laboratories USD 802.9M 398.8M 2026-03
Boston Scientific USD 11.01B 19M 2025-12
Cooper Companies USD 1.88B 578.5M 2025-12
Danaher USD 17.56B 855M 2026-03
Dentsply International USD 2.01B 9M 2026-03
Dexcom USD 1.3B 54.4M 2026-03
Edwards Lifesciences USD 600M 1.7M 2026-03
Globus Medical USD 436K 9K 2025-12
Insulet USD 929.5M 1.3M 2026-03
Integra LifeSciences USD 1.83B 29.45M 2026-03
Intuitive Surgical USD 0 0 2025-03
J&J USD 37.53B 1.91B 2026-03
Masimo USD 445.7M 72.3M 2026-03
Medtronic USD 27.88B 255M 2025-12
Solventum Corp USD 4.58B 460M 2026-03
Stryker USD 14.22B 635M 2026-03
Tandem Diabetes Care USD 601.77M 291.73M 2026-03
Teleflex USD 2.51B 27.18M 2026-03
Terumo JPY 99.9B 12M 2025-12
Thermo Fisher Scientific USD 40.07B 4.22B 2026-03
Zimmer Biomet Holdings USD 6.3B 636.9M 2026-03